Amicus Therapeutics Projects 2024 Galafold Revenue Growth Of 11-16% At CER, Anticipates Full-Year Non-GAAP Profitability In 2024
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics forecasts an 11-16% revenue growth for Galafold in 2024 at constant exchange rates (CER) and expects to achieve full-year non-GAAP profitability in the same year.

February 28, 2024 | 12:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Amicus Therapeutics projects significant revenue growth for Galafold in 2024 and anticipates achieving non-GAAP profitability.
The projected revenue growth for Galafold, a key product for Amicus Therapeutics, indicates a positive outlook for the company's financial health and market performance. Achieving non-GAAP profitability is a significant milestone that could enhance investor confidence and potentially lead to a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100